Candel Therapeutics Inc.
February 20, 2025 - by Joey Ramson
$CADL is leading the Prism MarketView Pharmaceuticals index, today Citi began coverage on them, assigning a Buy rating and setting a price target of $25.00. The initiation comes in the wake of Candel’s lead asset, CAN-2409, showing promising results in the treatment of localized prostate cancer.
